Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 2/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTR1E | P28566 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15568747 | 1.00 | SLC6A9 (0.42) | SLC6A9MBTD1L3MBTL3ALDH1A1TP53 | |
| SCHEMBL24662205 | 0.94 | HTR1E (0.43) | SLC6A9MBTD1L3MBTL3MEN1LMNA | |
| SCHEMBL4242551 | 0.94 | HTR1E (0.47) | SLC6A9MBTD1L3MBTL3MEN1LMNA | |
| SCHEMBL30911380 | 0.92 | MEN1 (0.46) | MBTD1L3MBTL3ALDH1A1MEN1LMNA | |
| SCHEMBL27336300 | 0.92 | MEN1 (0.46) | MBTD1L3MBTL3ALDH1A1MEN1LMNA | |
| SCHEMBL30374644 | 0.81 | HTR1E (0.41) | SLC6A9MBTD1L3MBTL3ALDH1A1MEN1 | |
| SCHEMBL24662249 | 0.81 | SLC6A3 (0.53) | — | |
| SCHEMBL30375011 | 0.81 | SLC6A3 (0.53) | — | |
| SCHEMBL24662243 | 0.81 | HTR1E (0.41) | SLC6A9MBTD1L3MBTL3ALDH1A1MEN1 | |
| SCHEMBL30903019 | 0.81 | MEN1 (0.40) | SLC6A9MBTD1L3MBTL3MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042896-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2025-02-06 | — | — | US | disclosed |
| CN-117940404-A | Tricyclic compounds as Cbl-b inhibitors | 海南先声再明医药股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042896-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | CBLB, CBL, CBLC | SLC6A9 219/4885MBTD1 1219/4885L3MBTL3 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.